SDPI - Price has been consolidating for about a month and the MACD recently crossed. We also see a double bottom in December. With the price closing above the .23 fib level and the DI+ crossing the DI-on the ADX in recent days It looks like a bullish reversal is in coming.
Targeting: .9055, .9819, 1. 05in the short term.
RVPH - Food and Drug Administration (FDA) has notified the Company that it may proceed with Phase 3 clinical investigation of its lead candidate, brilaroxazine, a novel serotonin and dopamine receptor modulator for the treatment of schizophrenia.
Also watching: T, NLST, HALL, LTRX, IEP